The zynlonta market research report is one of a series of new reports that provides zynlonta market statistics, including the zynlonta industry global market size, regional shares, competitors with the zynlonta market share, detailed zynlonta market segments, market trends, and opportunities, and any further data you may need to thrive in the zynlonta industry. This zynlonta market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to the rising incidence of lymphomas, increase in approvals and indications, growth in clinical trials, surge in combination therapies, growing awareness and diagnosis, and rising demand for targeted therapies. Major trends in the forecast period include technology advancements in immunotherapy, integration of biomarkers in treatment, innovation in antibody-drug conjugates, integration with digital health solutions, and developing advanced drug formulations.
The increasing incidence of lymphomas is expected to drive the growth of the zynlonta market in the coming years. Lymphomas are cancers that originate in the lymphatic system, primarily affecting lymphocytes, which are white blood cells found in the lymph nodes, spleen, bone marrow, and other lymphoid tissues. Factors contributing to the rising incidence of lymphomas include an aging population, immune system suppression, environmental exposures, viral infections, genetic predispositions, and lifestyle choices. Zynlonta is a targeted therapy designed to treat relapsed or refractory large B-cell lymphoma (LBCL) by delivering a chemotherapy drug directly to cancerous B cells, effectively killing them. For example, according to the American Cancer Society, the estimated number of new lymphoma cases increased from 89,010 in 2022 to 89,380 in 2023. Therefore, the rising incidence of lymphomas is driving the growth of the zynlonta market.
One of the key trends in the zynlonta market is the development of innovative therapies, such as combination therapies, to improve treatment efficacy and patient outcomes in cancer care. Combination therapies involve using two or more treatments, such as drugs or therapies, to enhance therapeutic effectiveness and target multiple aspects of a disease. For instance, in April 2024, ADC Therapeutics, a Switzerland-based biotechnology company, announced updates on their LOTIS-7 clinical trial. This trial evaluates Zynlonta (loncastuximab tesirine-lpyl) in combination with bispecific antibodies such as glofitamab or mosunetuzumab. The trial focuses on treating heavily pretreated patients with relapsed or refractory B-cell non-Hodgkin lymphoma (r/r B-NHL).
In July 2022, ADC Therapeutics, a Swiss biotechnology company specializing in developing antibody-drug conjugates (ADCs) for hematologic cancers and solid tumors, formed a partnership with Swedish Orphan Biovitrum AB (Sobi), a Sweden-based biopharmaceutical company. This strategic alliance aims to advance the development and commercialization of Zynlonta, expanding its availability in different regions and securing funding for ongoing clinical trials. Sobi specializes in treatments for hematology, immunology, and specialty care.
The key players in the zynlonta market are ADC Therapeutics SA, and Avid Bioservices Inc.
North America was the largest region in the zynlonta market in 2024. The regions covered in zynlonta report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the zynlonta market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Zynlonta (loncastuximab tesirine-lpyl) is a prescription medication used in oncology. It is a targeted therapy classified as an antibody-drug conjugate (ADC). Zynlonta is primarily indicated for the treatment of relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL), following two or more lines of systemic therapy.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for zynlonta include diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. DLBCL is an aggressive type of non-Hodgkin lymphoma (NHL) characterized by the rapid growth of large B-cells in the lymphatic system, typically treated with chemotherapy and immunotherapy, such as rituximab. Zynlonta is distributed through various channels including hospital pharmacies, retail pharmacies, and online pharmacies, and caters to various end users, including adult and geriatric patients.
The zynlonta market consists of sales of combination therapies, diagnostic and companion tools, supportive care medications, injection kits, and biosimilars. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to the rising incidence of lymphomas, increase in approvals and indications, growth in clinical trials, surge in combination therapies, growing awareness and diagnosis, and rising demand for targeted therapies. Major trends in the forecast period include technology advancements in immunotherapy, integration of biomarkers in treatment, innovation in antibody-drug conjugates, integration with digital health solutions, and developing advanced drug formulations.
The increasing incidence of lymphomas is expected to drive the growth of the zynlonta market in the coming years. Lymphomas are cancers that originate in the lymphatic system, primarily affecting lymphocytes, which are white blood cells found in the lymph nodes, spleen, bone marrow, and other lymphoid tissues. Factors contributing to the rising incidence of lymphomas include an aging population, immune system suppression, environmental exposures, viral infections, genetic predispositions, and lifestyle choices. Zynlonta is a targeted therapy designed to treat relapsed or refractory large B-cell lymphoma (LBCL) by delivering a chemotherapy drug directly to cancerous B cells, effectively killing them. For example, according to the American Cancer Society, the estimated number of new lymphoma cases increased from 89,010 in 2022 to 89,380 in 2023. Therefore, the rising incidence of lymphomas is driving the growth of the zynlonta market.
One of the key trends in the zynlonta market is the development of innovative therapies, such as combination therapies, to improve treatment efficacy and patient outcomes in cancer care. Combination therapies involve using two or more treatments, such as drugs or therapies, to enhance therapeutic effectiveness and target multiple aspects of a disease. For instance, in April 2024, ADC Therapeutics, a Switzerland-based biotechnology company, announced updates on their LOTIS-7 clinical trial. This trial evaluates Zynlonta (loncastuximab tesirine-lpyl) in combination with bispecific antibodies such as glofitamab or mosunetuzumab. The trial focuses on treating heavily pretreated patients with relapsed or refractory B-cell non-Hodgkin lymphoma (r/r B-NHL).
In July 2022, ADC Therapeutics, a Swiss biotechnology company specializing in developing antibody-drug conjugates (ADCs) for hematologic cancers and solid tumors, formed a partnership with Swedish Orphan Biovitrum AB (Sobi), a Sweden-based biopharmaceutical company. This strategic alliance aims to advance the development and commercialization of Zynlonta, expanding its availability in different regions and securing funding for ongoing clinical trials. Sobi specializes in treatments for hematology, immunology, and specialty care.
The key players in the zynlonta market are ADC Therapeutics SA, and Avid Bioservices Inc.
North America was the largest region in the zynlonta market in 2024. The regions covered in zynlonta report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the zynlonta market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Zynlonta (loncastuximab tesirine-lpyl) is a prescription medication used in oncology. It is a targeted therapy classified as an antibody-drug conjugate (ADC). Zynlonta is primarily indicated for the treatment of relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL), following two or more lines of systemic therapy.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for zynlonta include diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. DLBCL is an aggressive type of non-Hodgkin lymphoma (NHL) characterized by the rapid growth of large B-cells in the lymphatic system, typically treated with chemotherapy and immunotherapy, such as rituximab. Zynlonta is distributed through various channels including hospital pharmacies, retail pharmacies, and online pharmacies, and caters to various end users, including adult and geriatric patients.
The zynlonta market consists of sales of combination therapies, diagnostic and companion tools, supportive care medications, injection kits, and biosimilars. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Zynlonta Market Characteristics4. Zynlonta Market Trends And Strategies5. Zynlonta Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Zynlonta Pricing Analysis & Forecasts30. Global Zynlonta Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Zynlonta Market32. Recent Developments In The Zynlonta Market
3. Zynlonta Market Biologic Drug Characteristics
6. Global Zynlonta Growth Analysis And Strategic Analysis Framework
8. Zynlonta Market Segmentation
9. Global Zynlonta Epidemiology Of Clinical Indications
10. Zynlonta Market Regional And Country Analysis
11. Asia-Pacific Zynlonta Market
12. China Zynlonta Market
13. India Zynlonta Market
14. Japan Zynlonta Market
15. Australia Zynlonta Market
16. South Korea Zynlonta Market
17. Western Europe Zynlonta Market
18. UK Zynlonta Market
19. Germany Zynlonta Market
20. France Zynlonta Market
21. Eastern Europe Zynlonta Market
22. North America Zynlonta Market
23. USA Zynlonta Market
24. Canada Zynlonta Market
25. South America Zynlonta Market
26. Middle East Zynlonta Market
27. Africa Zynlonta Market
28. Zynlonta Market Competitive Landscape And Company Profiles
29. Global Zynlonta Market Pipeline Analysis
33. Zynlonta Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Zynlonta Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on zynlonta market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for zynlonta ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The zynlonta market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Diffuse Large B-Cell Lymphoma (DLBCL); High-Grade B-Cell Lymphoma; DLBCL Arising From Follicular Lymphoma2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End-User: Adult Patients; Geriatic Patients
Key Companies Profiled: ADC Therapeutics SA; Avid Bioservices Inc
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- ADC Therapeutics SA
- Avid Bioservices Inc
